Molecular mechanism of DAPD/DXG against zidovudine- and lamivudine- drug resistant mutants: A molecular modelling approach

Antiviral Chemistry and Chemotherapy

Volumn 13, Issue 2, 2002, Pages 115-128

  Chong, Youhoon ^a   Borroto Esoda, Katyna ^b   Furman, Phillip A ^b   Schinazi, Raymond F ^c   Chu, Chung K ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b Triangle Pharmaceuticals   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3TC; AZT; DAPD; Drug resistance; DXG; HIV 1 RT; Molecular modelling

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; 2,6 DIAMINOPURINE DIOXOLANE; ARGININE; BETA DEXTRO DIOXOLANE GUANINE; LAMIVUDINE; LYSINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TYROSINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; DRUG RESISTANCE; ENZYME INHIBITOR COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL;

EID: 0038240528     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020201300205     Document Type: Article

References (71)

1. Arion D, Kaushik N, McCormick S, Borkow G & Parniak MA (1998) Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37:15908-15917.
2. Arion D & Parniak MA (1999) HIV resistance to zidovudine: the role of pyrophosphorolysis. Drug Resisitance Updates 2:91-95.
3. Arts EJ & Wainberg MA (1996) Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrobial Agents & Chemotherapy 40:527-540.
4. Blaney JM, Weiner PK, Dearing A, Kollman PA, Jorgensen EC, Oatley SJ, Burridge JM & Blake CCF (1982) Molecular mechanics simulation of protein ligand interactions - binding of thyroidhormone analogs to pre-albumin. Journal of the American Chemical Society 104:6424-6434.
5. Boyer PL & Hughes SH (1995) Analysis of mutations at position-184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 39:1624-1628.
6. Boyer PL, Ferris AL, Clark P, Whitmer J, Frank P, Tantillo C, Arnold E & Hughes SH (1994) Mutational analysis of the fingers and palm subdomains of human immuinodeficiency virus type 1 (HIV-1) reverse transcriptase. Journal of Molecular Biology 243:472-483.
7. Boyer PL, Sarafianos SG, Arnold E & Hughes SH (2001) Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. Journal of Virology 75:4832-4842.
8. Boyer PL, Tantillo C, Jacobo-Molina A, Nanni RG, Ding J, Arnold E & Hughes SH (1994) Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length-the sensitivity of drug-resistant mutants does not. Proceedings of the National Academy of Sciences USA 91:4882-4886.
9. Cammack N, Rouse P, Marr CLP, Reid PJ, Boehme RE, Coates JAV, Penn CR & Cameron JM (1992) Cellular metabolism of(-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochemical Pharmacology 43:2059-2064.
10. Carpenter CCJ, Fishl ML, Hammer SM, Hirsch MS, Jacobson DM, Katzenstein DA, Montanger JSG, Richman DD, Saag MS, Schooley RT, Thompson MA, Valla S, Yani PG & Volberding PA (1997) Antiretroviral therapy for HIV infection in 1997. Update recommendations of the International AIDS Society-USA panel. Journal of the American Medical Association 277:1962-1969.
11. Carroll SS, Geib J, Olsen DB, Stahlhut M, Shafer JA & Kuo LC (1994) Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate. Biochemistry 332:113-2120.
12. Carter C W (1995) The nucleoside deaminases for cytidine and adenosine-structure, transition-state stabilization, mechanism, and evolution. Biohemie 77:92-98.
13. Chang CN, Doong SL, Zhou JH, Beach JW, Jeong LS, Chu CK, Tsai CH & Cheng YC (1992) Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. Journal of Biological Chemistry 267:13938-13942.
14. Chang CN, Skalski V, Zhou J & Cheng YC (1992) Biochemical pharmacology of (+)-2′,3′-dideoxy-3′-thiacytidine and (-)-2′,3′-dideoxy-3′-thiacytidine as antihepatitis B-virus agents. Journal of Biological Chemistry 267:22414-22420.
15. Ding JP, Das K, Hsiou Y, Sarafianos SG, Clark Jr AD, Jacobo-Molina A, Tantillo C, Hughes SH & Arnold E (1998) Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution. Journal of Molecular Biology 284:1095-1111.
16. Eriksson BFH, Schinazi RF & Chu CK (1988) Inhibition of HIV-1 and simian immunodeficiency virus (SIV) reverse transcriptases by the 5′-triphosphates of 3′-azido-2′,3′-dideoxyuridine (CS-87), 3′azido-3′-deoxyuthymidine (AZT), and 3′-azido-2′,3′-dideoxy-5-ethyluridine (CS-85). Antiviral Research 9:84-84.
17. Feng JY & Anderson KS (1999) Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase. Biochemistry 38:55-63.
18. Fridland A, Connelly MC & Robbins BL (2000) Cellular factors for resistance against antiretroviral agents. Antiviral Therapy 5:181-185.
19. Furman PA, Davis M, Liotta DC, Paff M, Frick LW, Nelson DJ, Dornsife RE, Wurster JA, Wilson LJ, Fyfe JA, Tuttle JV, Miller WH, Condreay L, Averett DR, Schinazi RF & Painter GR (1992) The anti-hepatitis-B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrobial Agents and Chemotherapy 36:2686-2692.
20. Furman PA, Jeffrey J, Keifer LL, Peng JY, Anderson JS, Borroto-Esoda K, Hill E, Copeland WC, Chu CK, Sommadossi JP, Liberman I, Schinazi RF & Painter GR (2001) Mechanism of action of 1-β-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-β-D-dioxolane guanosine. Antimicrobial Agents and Chemotherapy 45:158-165.
21. Furman PA, Painter G, Wilson JE, Cheng N & Hopkins S (1991) Substrate inhibition of the human immunodeficiency virus type 1 reverse transcriptase. Proceedings of the National Academy of Science USA 83:8333-8337.
22. Gao Q, Gu Z, Parniak MA, Li X & Wainberg MA (1992) In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. Journal of Virology 66:12-19.
23. Gästalger J & Marsili M (1980) Iterative partial equalization of orbital electronegativity - A rapid access to atomic charges. Tetrahedron. 36:3219-3228.
24. Gray NM, Marr CL, Penn CR, Cameron JL & Bethell RC (1995) The intracallular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA-polymerase γ. Biochemical Pharmacology 50:1043-1051.
25. Gu Z, Wainberg MA, Nguyen-Ba N, L'Heureux L, De Muys JM, Bowlin TL & Rando RF (1999) Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrobial Agents and Chemotherapy 43:2376-2382.
26. Hao Z, Cooney DA, Hartman NR, Perno CF, Fridland A, Devico AL, Sarngadharan MG, Broder S & Johns DG (1988) Factors determining the activity of 2′,3′-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Molecular Pharmacology 34:431-435.
27. Harrigan PR, Kinghorn I, Bloor S, Kemp SD, Najera I, Kohli A & Larder BA (1996) Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. Journal of Virology 70:5930-5934.
28. Hayes DM, Kollman PA (1976) Electrostatic potentials of proteins. 2. Role of electrostatics in a possible catalytic mechanism for carboxypeptidase-A. Journal of the American Chemical Society 98:3335-3345.
29. Hooker DJ, Tachedjian G, Solomon AE, Gurusinghe AD, Land S, Birch C, Anderson JL, Roy BM, Aronld E & Deacon NJ (1996) An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. Journal of Virology 70:8010-8018.
30. Huang H, Chopra R, Verdine G & Harrison S (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
31. Huber HE, McCoy JM, Seehra JS & Richardson CC (1989) Human immunodeficiency virus-1 reverse transcriptase-template binding, processivity, strand displacement synthesis, and template switching. Journal of Biological Chemistry 264:4669-4678.
32. Iversen AFN, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B & Merigan TC (1996) Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. Journal of Virology 70:1086-1090.
33. Jacobo-Molina A, Ding J, Nanni RG, Clark Jr. AD, Lu XD, Tantillo C, Williams RL, Kamer G, Ferris AL, Clark P, Hizi A, Hughes SH & Arnold E (1993) Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double stranded DNA at 3.0 Ȧ resolution shows bent DNA. Proceeding of the National Academy of Sciences USA 90:6320-6324.
34. Jenuth JP, Mably ER & Snyder FF (1996) Modeling of purine nucleoside metabolism during mouse embryonic development. Relative routes of adenosine, deoxyadenosine and deoxyguanosine metabolism. Biochemistry and Cell Biology 74:219-225.
35. Kafi WM, Johnson KA, Jerva LF & Anderson KS (1992) Mechanism and fidelity of HIV reverse transcriptase. Journal of Biological Chemistry 267:25988-25997.
36. Kellam P, Boucher CA & Larder BA (1992) Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proceedings of the National Academy of Sciences USA 89:1934-1938.
37. Kerr SG & Anderson KS (1997) Pre-steady-state kinetic characterization of wild-type and 3′-azido-3′-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance. Biochemistry 36:14064-14070.
38. Kim HO, Ahn SK, Alves AJ, Beach JW, Jeong LS, Choi BG, Vanroey P, Schinazi RF & Chu CK (1992) Asymmetric synthesis of 1,3-dioxolane pyrimidine nucleosides and their anti-HIV activity. Journal of Medicinal Chemistry 35:1987-1995.
39. Kim HO, Schinazi RF, Nampalli S, Shanmuganathan K, Cannon DL, Alves AJ, Jeong LS, Beach JW & Chu CK (1993) 1,3-Dioxolanylpurine nucleosides (2R, 4R) and (2R, 4S) with selective anti-HIV-1 activity in human lymphocytes. Journal of Medicinal Chemistry 36:30-37.
40. Kimberlin DW, Coen DM, Biron KK, Cohen JI, Lamb RA, McKinlay M, Emini EA & Whitley RJ (1995) Molecular mechanisms of antiviral resistance. Antiviral Research 26:369-401.
41. Krebs R, Immendörfer U, Thrall SH, Wohrl BM & Goody RS (1997) Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3TC. Biochemistry 36:10292-10300.
42. Lacey SF, Reardon JE, Furfine ES, Kunkel TA, Bebenek K, Eckert KA, Kemp SD & Larder BA (1992) Biochemical studies on the reverse transcriptase and RNAse H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. Journal of Biological Chemistry 267:15789-15794.
43. Larder BA & Kemp SD (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to Zidovudine (AZT). Science 246:1155-1158.
44. Larder BA & Stammers DK (1999) Closing in on HIV drug resistance. Nature Structural Biology 6:103-106.
45. Larder BA (1992) AZT resistance suppressed by a mutation conferring HIV-1 resistance to non-nucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy 36:1171-1174.
46. Lee K & Chu CK (2001) Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents. Antimicrobial Agents and Chamotherapy 45:138-144.
47. Matthes E, Lehmann C, Scholtz D, von Janta-Lipinski M, Gaertner K, Rosenthal HA & Langen P (1987) Inhibition of HIV-associated reverse transcriptase by sugar-modified derivatives of thymidine 5′-triphosphate in comparison to cellular DNA polymerase α and β. Biochemical and Biophysical Research Communications 148:78-85.
48. Mewshaw JP, Myrick FT, Wakefield DACS, Hooper BJ, Harris JL, McCreedy B & Borroto-Esoda K (2002) Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients failing standard nucleoside therapy. Journal of Acquired Immune Deficiency Syndromes 29:11-20.
49. Meyer PR, Matsuura SE, Mian AM, So AG & Scott WA (1999) A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Molecular Cell 4:35-43.
50. Meyer PR, Matsuura SE, So AG & Scott WA (1998) Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide dependent mechanism. Proceedings of the National Academy of Sciences USA 95:13471-13476.
51. Moyle GJ (1995) Resistance to antiretroviral compounds: implications for the clinical management of HIV infection. Immunology Infectious Diseases 5:170-182.
52. Painter GR, Aulabaugh AE & Andrew CW (1993) A comparison of the conformations of the 5′-triphosphates of zidovudine (AZT) and thymidine bound to HIV-1 reverse transcriptase. Biochemical and Biophysical Research Communications 191:1166-1171.
53. Painter GR, Wright LL, Hopkins S & Furman PA (1991) Initial binding of 2′-deoxynucleoside 5′-triphosphates to hyman immunodeficiency virus type 1 reverse transcriptase. Journal of Biological Chemistry 266:19362-19368.
54. Preston BD, Poiesz BJ & Loeb LA (1988) Fidelity of HIV-1 reverse transcriptase. Science 242:1168-1171.
55. Purcell WP & Singer JA (1967) A brief review and table of semiempirical parameters used in Hückel molecular orbital method. Journal of Chemical & Engineering Data 12:235-246.
56. Roberts JD, Bebenek K & Kunkel TA (1988) The accuracy of reverse transcriptase from HIV-1. Science 242:1171-1173.
57. Sarafianos SG, Kalyan D, Clark, Jr AD, Ding J, Boyer PL, Hughes SH & Arnold E (1999) Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with βbranched amino acids. Proceedings of the National Academy of Sciences USA 96:10027-10032.
58. Schinazi RF, McMillan A, Cannon D, Mathis R, Lloyd RM, Peck A, Sommadossi JP, St. Clar MH, Wilson J, Furman PA, Painter G, Choi WB & Liotta DC (1992) Selective inhibition of human immmunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrobial Agents and Chemotherapy 36:2423-2431.
59. Schinazi RF, Larder BA & Mellors JW (2000) Mutations in retroviral genes associated with drug resistance. International Antiviral News 8:129.
60. Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, Chokekijchai S, Roy BM, Arnold E, Yarchoan R & Mitsuya H (1995) Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proceedings of the National Academy of Sciences USA 92:2398-2402.
61. Siddiqui MA, Brown WL, Nguyen-Ba N, Dixit DM & Mansour TS (1993) Antiviral optically pure dioxolane purine nucleoside analog. Bioorganic & Medicinal Chemistry Letters 3:1543-1546.
62. Skalski V, Chang CN, Dutschman G & Cheng YC (1993) The biochemical basis for the differential anti-human-immunodeficiency-virus activity of 2 cis enantiomers of 2′,3′-dideoxy-3′-thiacytidine. Journal of Biological Chemistry 168:23234-23238.
63. Sluis-Cremer N, Arion D & Parniak MA (2000) Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cellular and Molecular Life Science 57:1408-1422.
64. St. Clair MH, Martin JL, TudorWilliams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD & Larder BA (1991) Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
65. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PAJ & Arnold E (1994) Locations of anti-AIDS drug binding sites and resistance mutations in the 3-dimensional structure of HIV-1 reverse transcriptase-implications for mechanisms of drug-inhibition and resistance. Journal of Molecular Biology 243:369-387.
66. Van Roey P, Salerno JM, Duax WL, Chu CK, Anh MK & Schinazi RF (1988) Solid-state conformation of anti-human immunodeficiency virus type-1 agents-Crystal structure of 3′-azido-3′deoxythymidine analogs. Journal of the American Chemical Society 110:2277-2282.
67. Weiner SJ, Kollman PA, Nguyen DT, Case DA (1986) An all atom force-field for simulations of proteins and nucleic-acids. Journal of Computaional Chemistry 7:230-252.
68. West AB, Roberts T. M & Kolodner RD (1992) Regulation of the reverse transcriptase of human immunodeficiency virus type 1 by dNTPs. Proceedings of the National Academy of Sciences USA 89:9720-9724.
69. Wipff G, Dearing A, Weiner PK, Blaney JM, Kollman PA (1983) Molecular mechanics studies of enzyme-substrate interactions-The interaction of L-N-acetylryptophanamide and D-N-acetyltryptophanamide with α-chymotrypsin. Journal of the American Chemical Society 105:997-1005.
70. Yao SYM, Cass C. E & Young JD (1996) Transport of the antiviral nucleoside analogs 3′-azido-3′-deoxythymidine and 2′,3′-dideoxycytidine by a recombinant nucleoside transporter (rCNT) expressed in Xenopus laevis. Molecular Pharmacology 50:388-393.
71. Yu H & Goodman MF (1992) Comparison of HIV-1 and avian myeloblastosis virus reverse transcriptase fidelity on RNA and DNA templates. Journal of Biological Chemistry 267:10888-10896.